Can I continue to take Axitinib after becoming resistant to it?

Axitinib is an oral, small molecule tyrosine kinase inhibitor mainly used to treat advanced renal cell carcinoma. It blocks tumor angiogenesis by inhibiting vascular endothelial growth factor receptor (VEGFR) to inhibit tumor growth. However, with the prolongation of treatment time, some patients may develop drug resistance, that is, the tumor's therapeutic effect on axitinib gradually weakens or fails, which poses challenges to subsequent treatment.

When a patient develops resistance to axitinib, whether to continue taking it needs to be judged based on the specific situation. Generally speaking, if the tumor progresses significantly and the treatment effect is significantly weakened, simply continuing to use axitinib may not bring significant benefit. At this time, doctors usually consider adjusting the treatment plan, such as changing to other targeted drugs, combining immunotherapy, or participating in clinical trials, in order to obtain better results. Continuing ineffective treatment not only increases the risk of drug side effects, but may also delay the opportunity for more effective treatment.

On the other hand, in some cases, doctors may recommend continuing to use axitinib in the early stages of resistance, while adding other drugs for combination therapy in order to delay the progression of resistance. For example, some studies have explored the combined use of axitinib and immune checkpoint inhibitors, showing certain clinical potential. Whether to continue using it should be evaluated and decided by a professional medical team based on the patient's physical condition, tumor burden, and treatment tolerance.

In general, whether to continue taking axitinib after drug resistance is not a simple "yes" or "no" question. Patients should choose the most appropriate follow-up treatment plan according to their individualized condition and treatment response under the guidance of a professional doctor. Reasonable treatment adjustments and multidisciplinary comprehensive management can help prolong patients' survival and improve their quality of life.

Reference materials:https://en.wikipedia.org/wiki/Axitinib